EIC Transition Programme: Scope Biosciences

Niek himself studied biotechnology at WUR. During his studies, he worked on diagnostics, building a valuable network within the Wageningen ecosystem, laying the foundation for his current company. Scope Biosciences has since secured several major investments, including half a million euros from impact investor SHIFT Invest through the Thematic Technology Transfer (TTT). The company has expanded to ten employees and is moving closer to market readiness.

Important Step Towards Practice

Niek: "The EIC Transition funding is a crucial step for us in making the leap to practical application. The aim of this grant is not necessarily to have a fully market-ready product but to get very close to that market introduction. Think of it this way: we are currently still somewhat of a biotech company focused primarily on developing reagents. We are using the grant to transform it into a comprehensive and user-friendly package for our customers, while also preparing to meet European quality standards. "

Mature Ecosystem

According to Niek, the entrepreneurial ecosystem in Wageningen has experienced impressive growth over the years. "Wageningen has developed a thriving hub for innovative startups and spin-offs. There are now various programmes and initiatives that support and guide emerging companies. As a result, the business climate has become increasingly professional and streamlined. Additionally, we have established an excellent research facility at the heart of the campus, keeping us close to the action. The vital collaboration with Wageningen University & Wageningen Research is progressing exceptionally well. I have witnessed WUR evolve over the years into an organisation that is far more proactive in fostering entrepreneurship. An institution that identifies and nurtures talent and helps create significant impact on society."

“Seek Support from RVO"

Niek concludes with a piece of advice for young entrepreneurs: "Securing a European grant can be quite challenging, with a generally low success rate. The application process is often very complex. As an entrepreneur, it's crucial to seek assistance from the Netherlands Enterprise Agency (RVO). They have been immensely helpful in preparing us for the EIC interview, and we have greatly benefited from their support."

Scope Biosciences: Rapid detection of genetic material

The Wageningen spin-off Scope Biosciences is a leader in CRISPR-Cas diagnostics. This groundbreaking technology, awarded the Nobel Prize in Chemistry in 2020, has revolutionised molecular biology and genetics by allowing precise editing of genetic codes. Its applications extend beyond genetic manipulation.

Scope Biosciences leverages the precision and user-friendliness of CRISPR-Cas to advance molecular diagnostics, enabling rapid and highly accurate testing outside traditional laboratories. The spin-off is currently focused on commercialising this technology in both healthcare and the agrifood sector. In healthcare, they are partnering with companies such as GenDx in Utrecht to develop tests for organ and stem cell transplants.

In the agrifood sector, Scope Biosciences is closer to market readiness. The company is developing agricultural tests that can rapidly and on-site detect plant diseases, facilitating timely and precise treatment. This diagnostic platform supports sustainable and efficient agriculture, as early disease detection minimises its impact on crops.

The technology behind Scope Biosciences is based on the pioneering research of WUR scientists John van der Oost and Raymond Staals.

More about Scope Biosciences: www.scopebio.com